SHIONOGI's Spotfire Data Science Story

In July 2024, SHIONOGI presented their Spotfire usage at Spotfire Pharmaceutical Workshop Seoul.














SHIONOGI's company-wide data utilization initiatives and how Spotfire is used

07.04.24 Shionogi & Co, Ltd. DX Promotion Division Data Science Department Director Shinichi Fukunaga





The presentation, delivered by Shinichi Fukunaga san from the Data Science Department of Shionogi, is titled "SHIONOGI's Company-wide Data Utilization Initiatives and How Spotfire is Used."

It is divided into two parts: an overview of Shionogi's data initiatives and specific Spotfire use cases, which will be introduced by Masayuki Kobayashi san in the second half. Shinichi Fukunaga-san outlined his career, highlighting his experience as a medical representative since 1996 and his transition to data warehousing and data science roles from 2020. Shionogi, a Japanese pharmaceutical company established in 1878, is focused on its 2030 vision of "Creating the Future of Healthcare on a New Platform," including AI-SAS development. The company specializes in areas like infectious diseases, the central nervous system, and cancer pain.




The Data Science Department, positioned under the DX Promotion Division alongside IT, plays a critical role in achieving digital transformation (DX). Collaboration between these departments is key to Shionogi's success, as evidenced by being recognized as a "DX Stock 2023" by Japan's Ministry of Economy, Trade, and Industry. Their work spans the entire value chain, including research, clinical trials, sales, HR, and accounting.






A significant portion of the presentation introduced AI-SAS (Artificial Intelligence SAS), a system developed with SAS Institute Japan starting in 2016. AI-SAS operates in three steps: recognition, learning, and action. It analyzes clinical trial data and semi-automatically generates programs, significantly improving efficiency. Version 1, released in late 2017, achieved a 20% business improvement, while Version 2, released in 2018, improved productivity by 33%, reducing standard programming time by 100 hours. AI-SAS has been recognized both internally and externally for its impact.



Shinichi Fukunaga san explained the changes in the number of users of Spotfire Analyst and Spotfire Consumer at Shionogi, using data from 2013 onwards. In particular, we can see that the number of daily users exceeded 1,000 around the time of covid19 treatment in the latter half of 2022. Looking at the number of users in the sales department, the growth in the number of users has clearly increased sharply since the latter half of 2022.



A significant portion of the presentation introduced AI-SAS (Artificial Intelligence SAS), a system developed with SAS Institute Japan starting in 2016. AI-SAS operates in three steps: recognition, learning, and action. It analyzes clinical trial data and semi-automatically generates programs, significantly improving efficiency. Version 1, released in late 2017, achieved a 20% business improvement, while Version 2, released in 2018, improved productivity by 33%, reducing standard programming time by 100 hours. AI-SAS has been recognized both internally and externally for its impact.

Leveraging Spotfire for Clinical Research


Efficiency and Beyond: Expanding SHIONOGI's Capabilities

07.04.24 Shionogi & Co, Ltd. Department of Data Science, DX Promotion Division





In the second half of presentation "Leveraging Spotfire for Clinical Research Efficiency and Beyond: Expanding SHIONOGI's Capabilities" by Masayuki Kobayashi san, a member of Shionogi's Data Science Department, at the Spotfire Pharmaceutical Workshop 2024 in Seoul focuses on leveraging Spotfire to enhance clinical research efficiency and explores its broader applications.





Introduction and Background:


- Masayuki Kobayashi san's background includes roles in pharmaceutical sales and digital transformation within Shionogi.
- The presentation emphasizes the importance of interactive visualization in unlocking data value for clinical research.


Using Spotfire in Clinical Research:


- Spotfire excels in post-marketing clinical research, enabling the testing of unverified hypotheses and generating new ones.
- The analysis process is outlined in three steps:
 - 1. Examining data distributions.
 - 2. Evaluating relationships between variables.
 - 3. Stratifying visualizations to uncover insights.














Advantages of Spotfire:

- Facilitates dynamic and interactive analysis, especially during discussions with medical and non-statistical professionals.
- Simplifies complex tasks, such as survival analysis and decision tree modeling, by integrating R and Python functions.











Expanding Spotfire's Capabilities:


- Future plans include greater integration with SAS language and leveraging real-world data for actionable insights.
- xamples include adherence rate visualization, patient journey analysis, and sales forecasting.












Impact on Analysts:

- Spotfire transforms analysts' roles from data processors to key players in driving business digital transformation.
- Kobayashi san stresses the need for interactive analytics to democratize data-driven decision-making.



Conclusion:

- Encourages adopting Spotfire to turn one-way meetings into collaborative, interactive sessions.
- Advocates expanding the "circle of co-creation" by leveraging Spotfire's capabilities.

Conclusion and Summary How should we effectively utilize Spotfire? To transform one-way meetings into interactive discussions, making analyses interactive is essential. Analysts have the potential to drive business transformation through Spotfire. Let's expand the circle of co-creation by leveraging this exciting tool!

Shionogi's presentation showcases how Spotfire is integral to advancing Shionogi's data-driven initiatives, offering a vision for broader use in clinical and business contexts.





Revvity Signals appreciated Shionogi's Spotfire usage and collaboration.

